A Nature Communications study reported that STING agonist 8803 inhibited tumor growth in human meningioma samples and reduced tumor volume and mortality in mouse models. Researchers found the STING pathway is expressed in both meningioma tumor cells and immune cells in the tumor microenvironment.
St. Jude researchers linked specific childhood cancer therapies to DNA fingerprints in second neoplasms, potentially improving survivor surveillance and guiding safer treatments. Separately, the Global Platform for Access to Childhood Cancer Medicines has helped Nepal and Ghana build national cancer registries and implement national strategies.
Northwestern Medicine researchers identified a potent immunotherapy approach targeting the STING pathway for meningiomas, the most common primary brain tumor. The experimental drug STING agonist 8803 triggered tumor cell death and immune responses in human samples and mouse models.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07713745 |
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07708285 |
Luvometinib in Combination With Serplulimab for NF2-Related Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07707947 |
Selumetinib for NF2-Related Schwannomatosis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07652762 |
IN10018 in Combination With Dalpiciclib for Progressive Meningiomas |
RECRUITING | PHASE1 |
| NCT07533942 |
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma |
RECRUITING | PHASE2 |
| NCT07493447 |
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures |
RECRUITING | EARLY_PHASE1 |
| NCT07428616 |
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma |
RECRUITING | PHASE2 |
| NCT07398170 |
Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study |
RECRUITING | NA |
| NCT06607692 |
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). |
RECRUITING | PHASE1/PHASE2 |
| NCT06126588 |
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial |
RECRUITING | PHASE2 |
